- Stocks
- Pharma & Healthcare
- Norris Medicine
Norris Medicine share price
NSE: NORRISPharma & HealthcareDrug Manufacturers - Specialty & Generic
Norris Medicine at a glance
With a market capitalisation of ₹14 Cr, it ranks 3771st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1 Cr (−48.2% year on year) and net profit ₹0 Cr, on a standalone basis. Promoters held 34.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹14 CrRank 3771 on NSE
- Price to book
- -1.12×FY25
- EPS (TTM)
- −₹0.28to Q4 FY26
- ROE
- 0.0%FY25
- ROCE
- −20.2%FY25
- Debt to equity
- -1.45FY25
- Net profit margin
- −21.3%FY25
- Book value / share
- −₹14.98FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Norris Medicine quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹1 Cr |
| Revenue YoY | −24.2% | −50.4% | +70.8% | +82.6% | +102.8% | +57.5% | +194.6% | −48.2% |
| Net profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | — | — | — | −235.3% | — | — | — | — |
| Net margin | −51.4% | −28.3% | −25.2% | −8.5% | −21.2% | −36.0% | 21.4% | 3.5% |
| EPS | −₹0.37 | −₹0.36 | −₹0.28 | −₹0.23 | −₹0.31 | −₹0.72 | ₹0.70 | ₹0.05 |
Norris Medicine financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹12 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹6 Cr |
| Operating profit | −₹4 Cr | −₹4 Cr | −₹2 Cr | −₹1 Cr | −₹1 Cr | −₹1 Cr |
| Net profit | −₹3 Cr | −₹5 Cr | −₹3 Cr | −₹2 Cr | −₹1 Cr | −₹1 Cr |
| EPS (₹) | −₹2.84 | −₹4.96 | −₹3.26 | −₹1.75 | −₹1.19 | −₹1.24 |
| Cash from operations | −₹3 Cr | ₹1 Cr | −₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Total debt | ₹15 Cr | ₹16 Cr | ₹18 Cr | ₹18 Cr | ₹19 Cr | ₹19 Cr |
| Shareholders' equity | −₹2 Cr | −₹7 Cr | −₹11 Cr | −₹12 Cr | −₹14 Cr | −₹15 Cr |
Norris Medicine shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 34.00% | 34.00% | 34.00% | 34.00% | 34.01% | 34.01% |
| Domestic institutions | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% |
| Non-institutions | 65.93% | 65.93% | 65.93% | 65.93% | 65.92% | 65.92% |
Norris Medicine vs peers
The listed Pharma & Healthcare companies nearest to Norris Medicine by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| FAMILYCAREFamily Care Hos | — | — | — | ₹16 Cr | — | — |
| COLINZColinz Labs | — | — | — | ₹15 Cr | — | — |
| STARSOURCEStarsource Mult | — | — | — | ₹14 Cr | — | — |
| NORRISNorris Medicine | — | — | — | ₹14 Cr | — | — |
| DOLPHMEDDolphin Medical | — | — | — | ₹12 Cr | — | — |
| ORTINGLOBEORTIN GLOBAL | ₹13.53 | −6.04% | +16.6% | ₹11 Cr | — | — |
| BERLDRGBeryl Drugs | — | — | — | ₹11 Cr | — | — |
Ask anything about Norris Medicine
Pivot answers on the live chart with evidence you can check, and tests strategies against NORRIS's own history. Try: “Why has NORRIS moved over the last three months?” · “Backtest a 50-day moving-average crossover on NORRIS over five years” · “Compare NORRIS with FAMILYCARE on margins and valuation”
Frequently asked questions about Norris Medicine
What is the market cap of Norris Medicine?
Norris Medicine's market capitalisation is ₹14 Cr (₹14 Cr) at the 22 Oct 2026 close, ranking 3771st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Norris Medicine?
Return on equity was 0.0% in FY25 and return on capital employed was −20.2% in FY25 (standalone figures).
Is Norris Medicine a debt-free company?
Norris Medicine is close to debt-free: its debt-to-equity ratio was -1.45 in FY25.
What were Norris Medicine's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Norris Medicine reported revenue of ₹1 Cr, −48.2% year on year, and net profit of ₹0 Cr.
What is the shareholding pattern of Norris Medicine?
As of 30 Jun 2026: promoters 34.01%, domestic institutions 0.07%, non-institutions 65.92%.
Who are Norris Medicine's competitors?
The listed Pharma & Healthcare companies closest to Norris Medicine by market cap are Family Care Hos, Colinz Labs, Starsource Mult, Dolphin Medical, ORTIN GLOBAL and Beryl Drugs.
Is Norris Medicine a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Norris Medicine's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NORRIS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text